Citius Oncology Files 8-K Report

Ticker: CTOR · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1851484

Citius Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyCitius Oncology, INC. (CTOR)
Form Type8-K
Filed DateOct 23, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials

TL;DR

Citius Oncology filed an 8-K on Oct 23, 2025, covering Reg FD and financials. Formerly TenX Keane.

AI Summary

On October 23, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as TenX Keane Acquisition until March 15, 2021, is incorporated in Delaware and headquartered in Cranford, NJ.

Why It Matters

This 8-K filing provides updates on Citius Oncology's regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report detailing disclosures and financial statements, not indicating any immediate material events or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was Citius Oncology, Inc. formerly known as?

Citius Oncology, Inc. was formerly known as TenX Keane Acquisition.

On what date was the name change from TenX Keane Acquisition to Citius Oncology, Inc. effective?

The date of the name change was March 15, 2021.

Where are Citius Oncology, Inc.'s principal executive offices located?

Citius Oncology, Inc.'s principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.

What is the telephone number for Citius Oncology, Inc.?

The telephone number for Citius Oncology, Inc. is (908) 967-6677.

Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-23 17:09:05

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 23, 2025, Citius Oncology, Inc. posted an updated Corporate Presentation on its website. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit is filed herewith: Exhibit No. Description 99.1 Corporate Presentation of October 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: October 23, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing